In the DESTINY‐PanTumor02 trial, which included 267 patients covering various tumor types such as endometrial cancer, cervical cancer, ovarian cancer, bladder cancer, and bile duct cancer, DS‐8201 demonstrated significant efficacy in multiple HER2‐positive solid tumors. This evidence concerns the gene ERBB2 and neoplasm.